Fractional carbon dioxide laser-assisted drug delivery of topical timolol solution for the treatment of deep infantile hemangioma: A pilot study

Pediatric Dermatology

Volumn 31, Issue 3, 2014, Pages 286-291

  Ma, Gang ^a   Wu, Pinru ^b   Lin, Xiaoxi ^a   Chen, Hui ^a   Hu, Xiaojie ^a   Jin, Yunbo ^a   Qiu, Yajing ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON DIOXIDE; TIMOLOL MALEATE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; TIMOLOL;

ARTICLE; CAPILLARY HEMANGIOMA; CARBON DIOXIDE LASER; CHILD; CLINICAL ARTICLE; DENSITY; DRUG DELIVERY SYSTEM; DRUG PENETRATION; FEMALE; HEMANGIOMA ACTIVITY SCORE; HUMAN; INFANT; LOW LEVEL LASER THERAPY; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NEWBORN; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SKIN SURFACE; TREATMENT DURATION; CLINICAL TRIAL; FEASIBILITY STUDY; GAS LASER; HEMANGIOMA; MULTIMODALITY CANCER THERAPY; PROCEDURES; SEVERITY OF ILLNESS INDEX; SKIN NEOPLASMS; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; ADRENERGIC BETA-ANTAGONISTS; COMBINED MODALITY THERAPY; FEASIBILITY STUDIES; FEMALE; HEMANGIOMA; HUMANS; INFANT; LASER THERAPY; LASERS, GAS; MALE; PILOT PROJECTS; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SKIN NEOPLASMS; TIMOLOL; TREATMENT OUTCOME;

EID: 84899519262     PISSN: 07368046     EISSN: 15251470     Source Type: Journal    
DOI: 10.1111/pde.12299     Document Type: Article

References (25)

1. Kilcline C, Frieden IJ,. Infantile hemangiomas: how common are they? A systematic review of the medical literature. Pediatr Dermatol 2008; 25: 168-173.
2. Leonardi-Bee J, Batta K, O'Brien C, et al. Interventions for infantile haemangiomas (strawberry birthmarks) of the skin. Cochrane Database Syst Rev 2011; 11: CD006545.
3. Bruckner AL, Frieden IJ,. Hemangiomas of infancy. J Am Acad Dermatol 2003; 48: 477-493; quiz 494-496.
4. Léauté-Labrèze C, Dumas de la Roque E, Hubiche T, et al. Propranolol for severe hemangiomas of infancy. N Engl J Med 2008; 358: 2649-2651.
5. Schiestl C, Neuhaus K, Zoller S, et al. Efficacy and safety of propranolol as first-line treatment for infantile hemangiomas. Eur J Pediatr 2011; 170: 493-501.
6. Guo S, Ni N,. Topical treatment for capillary hemangioma of the eyelid using beta-blocker solution. Arch Ophthalmol 2010; 128: 255-256.
7. Oranje AP, Janmohamed SR, Madern GC, et al. Treatment of small superficial haemangioma with timolol 0.5% ophthalmic solution: a series of 20 cases. Dermatology 2011; 223: 330-334.
8. Xue K, Hildebrand GD,. Topical timolol maleate 0.5% for infantile capillary haemangioma of the eyelid. Br J Ophthalmol 2012; 96: 1536-1537.
9. Chakkittakandiyil A, Phillips R, Frieden IJ, et al. Timolol maleate 0.5% or 0.1% gel-forming solution for infantile hemangiomas: a retrospective, multicenter, cohort study. Pediatr Dermatol 2012; 29: 28-31.
10. Chambers CB, Katowitz WR, Katowitz JA, et al. A controlled study of topical 0.25% timolol maleate gel for the treatment of cutaneous infantile capillary hemangiomas. Ophthal Plast Reconstr Surg 2012; 28: 103-106.
11. Moehrle M, Léauté-Labrèze C, Schmidt V, et al. Topical timolol for small hemangiomas of infancy. Pediatr Dermatol 2013; 30: 245-249.
12. Semkova K, Kazandjieva J,. Topical timolol maleate for treatment of infantile haemangiomas: preliminary results of a prospective study. Clin Exp Dermatol 2013; 38: 143-146.
13. Andrews S, Lee JW, Choi SO, et al. Transdermal insulin delivery using microdermabrasion. Pharm Res 2011; 28: 2110-2118.
14. Gõmez C, Benito M, Teijõn JM, et al. Novel methods and devices to enhance transdermal drug delivery: the importance of laser radiation in transdermal drug delivery. Ther Deliv 2012; 3: 373-388.
15. 2 laser-assisted drug delivery. Lasers Surg Med 2010; 42: 113-122.
16. 2 laser pretreatment. Lasers Surg Med 2011; 43: 804-813.
17. 2 laser: a randomized clinical trial. Br J Dermatol 2012; 166: 1262-1269.
18. Kaila T, Karhuvaara S, Huupponen R, et al. The analysis of plasma kinetics and beta-receptor binding and blocking activity of timolol following its small intravenous dose. Int J Clin Pharmacol Ther Toxicol 1993; 31: 351-357.
19. Janmohamed SR, de Waard-van der Spek FB, Madern GC, et al. Scoring the proliferative activity of haemangioma of infancy: the Haemangioma Activity Score (HAS). Clin Exp Dermatol 2011; 36: 715-723.
20. Gomez C, Costela A, Garcia-Moreno I, et al. Skin laser treatments enhancing transdermal delivery of ALA. J Pharm Sci 2011; 100: 223-231.
21. Zhang Z, Fei Y, Chen X, et al. Comparison of a fractional microplasma radio frequency technology and carbon dioxide fractional laser for the treatment of atrophic acne scars: a randomized split-face clinical study. Dermatol Surg 2013; 39: 559-566.
22. McMahon P, Oza V, Frieden IJ,. Topical timolol for infantile hemangiomas: putting a note of caution in "cautiously optimistic." Pediatr Dermatol 2012; 29: 127-130.
23. Cante V, Pham-Ledard A, Imbert E, et al. First report of topical timolol treatment in primarily ulcerated perineal haemangioma. Arch Dis Child Fetal Neonatal Ed 2012; 97: F155-F156.
24. Khunger N, Pahwa M,. Dramatic response to topical timolol lotion of a large hemifacial infantile haemangioma associated with PHACE syndrome. Br J Dermatol 2011; 164: 886-888.
25. Berk DR, Lehman PA, Franz TJ, et al. On topical timolol gel-forming solution for infantile hemangiomas. Pediatr Dermatol 2013; 30: 160-161.